Form 4: William Scully Reports Changes in Prothena Corp Public Ltd Co Beneficial Ownership
SEC Form 4
William Scully, a director and 10% owner of Prothena Corp Public Ltd Co, reports multiple transactions involving ordinary shares between December 2024 and January 2025.
Summary
- William Scully, a director and 10% owner of Prothena Corp Public Ltd Co, filed a Form 4 detailing changes in beneficial ownership.
- The transactions involve the acquisition and disposal of ordinary shares, par value $0.01 per share.
- On December 18, 2024, Scully acquired 430,000 shares at $0 and purchased 73,436 shares at a weighted average price of $13.926.
- On December 19, 2024, Scully disposed of 681,000 shares at $0.
- On December 20, 2024, Scully purchased 2,000 shares at $15.9065 and disposed of 500 shares at $0.
- On December 31, 2024, Scully purchased 1,200 shares at $13.3652, 800 shares at $13.394, and 30,000 shares at a weighted average price of $12.988.
- On January 2, 2025, Scully disposed of 13,200 shares at $0.
- On January 3, 2025, Scully disposed of 1,000 shares at $0.
- On January 14, 2025, Scully purchased 100,000 shares at a weighted average price of $12.7904.
- On December 20, 2024, Scully disposed of 40,000 shares held by spouse at $0.
- On January 15, 2025, Scully disposed of 12,000 shares held by spouse at $0.
- Following these transactions, Scully directly owns 735,993 shares, indirectly owns 47,000 shares through his spouse, 75,950 shares through Manatee Equity Fund LLC, and 68,000 shares as trustee for The 2012 Randolph Scully Family Trust.
Sentiment
Score: 5
Explanation: This is a neutral report of transactions. The sentiment is neither positive nor negative without additional context.
Industry Context
Form 4 filings are a routine part of insider trading regulations, providing transparency into the buying and selling activities of company insiders. These filings are closely watched by investors as they can provide signals about management's view of the company's prospects.
Comparison to Industry Standards
- Comparing Scully's transactions to those of other directors or major shareholders in similar biotech companies could provide context.
- For example, if other insiders are also buying shares, it might signal confidence in the company's future prospects.
- Conversely, widespread selling by insiders could raise concerns.
- Analyzing the timing and size of these transactions relative to major company announcements (e.g., clinical trial results, regulatory approvals) is also important.
Stakeholder Impact
- Shareholders may react to the reported transactions, potentially influencing the stock price.
- The transactions could be interpreted as a signal of confidence or lack thereof from a key insider.
Key Dates
| Date | Description |
|---|---|
| 12/18/2024 | Acquisition of 430,000 shares at $0 and purchase of 73,436 shares at a weighted average price of $13.926. |
| 12/19/2024 | Disposal of 681,000 shares at $0. |
| 12/20/2024 | Purchase of 2,000 shares at $15.9065 and disposal of 500 shares at $0; disposal of 40,000 shares held by spouse at $0. |
| 12/31/2024 | Purchase of 1,200 shares at $13.3652, 800 shares at $13.394, and 30,000 shares at a weighted average price of $12.988. |
| 01/02/2025 | Disposal of 13,200 shares at $0. |
| 01/03/2025 | Disposal of 1,000 shares at $0. |
| 01/14/2025 | Purchase of 100,000 shares at a weighted average price of $12.7904. |
| 01/15/2025 | Disposal of 12,000 shares held by spouse at $0. |
| 05/02/2025 | Signature date of the report. |
Keywords
beneficial ownership, Form 4, securities, transactions, shares, Prothena, Scully
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.